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Abstract
Purpose: A review of the role of the carotenoids, lutein and zeaxanthin, and their function in
altering the pathogenesis of age-related macular degeneration (AMD).
Methods: Medline and Embase search.
Results: Recent evidence introduces the possibility that lutein and zeaxanthin, carotenoids found
in a variety of fruits and vegetables may protect against the common eye disease of macular
degeneration. This potential and the lack to slow the progression of macular degeneration, has
fueled high public interest in the health benefits of these carotenoids and prompted their inclusion
in various supplements. The body of evidence supporting a role in this disease ranges from basic
studies in experimental animals to various other clinical and epidemiological studies. Whilst some
epidemiological studies suggest a beneficial role for carotenoids in the prevention of AMD, others
are found to be unrelated to it. Results of some clinical studies indicate that the risk for AMD is
reduced when levels of the carotenoids are elevated in the serum or diet, but this correlation is
not observed in other studies. Published data concerning the toxicity of the carotenoids or the
optimum dosage of these supplements is lacking.
Conclusion: An intake of dietary supplied nutrients rich in the carotenoids, lutein and zeaxanthin,
appears to be beneficial in protecting retinal tissues, but this is not proven. Until scientifically sound
knowledge is available we recommend for patients judged to be at risk for AMD to: alter their diet
to more dark green leafy vegetables, wear UV protective lenses and a hat when outdoors. Future
investigations on the role of nutrition, light exposure, genetics, and combinations of photodynamic
therapy with intravitreal steroid (triamcinolone-acetonide) injections hold potential for future
treatment possibilities.
Introduction
The two major carotenoids in the human macula and ret-
ina are lutein and zeaxanthin [1,2]. Similar to β-carotene,
these pigments are found in various coloured fruits and
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cally consumed in the human diet [3,4], lutein and zeax-
anthin, are deposited at an up to 5 fold higher content in
the macular region of the retina [1] as compared to the
peripheral retina. Zeaxanthin is preferentially accumu-
lated in the foveal region [2,5], whereas lutein is abundant
in the perifoveal region. These pigments are collectively
referred to as the macular pigment (MP). Although the
role of the macular pigment remains uncertain, several
functions have been hypothesised and these include limi-
tation of the damaging photo-oxidative effects of blue
light through its absorption [6-8], reduction of the effects
of light scatter and chromatic aberration on visual per-
formance, [9,10], and protection against the adverse
effects of photochemical reactions because of the antioxi-
dant properties of the carotenoids [5,11,12].
Age related macular degeneration (AMD) is the leading
cause of irreversible vision loss in the elderly population
in the USA and the Western world. It is estimated that
1.6% of the population in the 50-to 65-year-old age group
is affected, rising to 30% in the over-75-year-old age
group. As the proportion of the elderly in our population
increases, the public health impact of AMD will become
even more severe Although the aetiopathogenesis of AMD
remains a matter of debate, there is a growing body of evi-
dence to indicate that oxidative damage plays a role
[13,14]. Consequently, the possibility that the absorption
characteristics and antioxidant properties of macular pig-
ment confer protection against age-related macular degen-
eration has been postulated [12,15] and it has further
been hypothesised that dietary supplementation with
lutein and / or zeaxanthin might protect the retina and /
or delay the progression of age-related macular degenera-
tion [12,16-18]. Supplementation with foods [19-21] or
supplements rich in lutein or zeaxanthin has been
reported to increase macular pigment density in most, but
not all, human subjects [19,21,22]. Yet despite the possi-
ble importance of these carotenoids in modulating the
course of age-related macular degeneration, critical evi-
dence of beneficial effect has not been found, and the role
that these carotenoid supplements play in patients with
age-related macular degeneration, or those at risk of devel-
oping the disease, remains unproved. In this article we
review the current literature present on carotenoids and
focus particularly on the controversial evidence that reti-
nal carotenoids are protective against age-related macular
degeneration.
Methods
Medline and Embase search.
Results
Age related macular degeneration
Definition and grading
In 1995 the International Age Related Maculopathy
(ARM) Study Group published the international classifi-
cation and grading system for age related maculopathy
and age related macular degeneration [23]. In this article
all age related macular changes are referred to as age
related maculopathy (ARM). ARM is a degenerative disor-
der involving the retinal pigment epithelium, choriocapil-
laries and retina which primarily, but not exclusively,
affects the macular region. Symptoms of ARM include
metamorphosia, impaired light adaptation and decreased
central vision. Age related macular degeneration (AMD) is
a term reserved for the late stages of ARM [23]. AMD has
been categorised in two forms, an exudative form charac-
terised by subretinal haemorrhage, detachment of retinal
pigment epithelium (RPE), choroidal neovascularization
(CNV), or retinal scarring and a "dry" form which
includes geographic atrophy. Once patients have reached
the late stage of this disease, vision loss cannot be restored
[24] and low vision aids are the only known help.
AMD remains the leading cause of legal blindness in the
elderly population in the Western world [25-27]. The risk
for AMD has been strongly linked to greater age [28], pos-
itive family history of AMD [29], smoking [30,31], female
gender [32], and finally the high intake of saturated fat
has been demonstrated to be related to early ARM as
shown in the Beaver Dam Eye Study [33]. Reports vary on
the relationship between light iris colour and the severity
of AMD or increase risk of for ARM [34-37]. It is estimated
that 1.6% of the population in the 50-to 65-year-old age
group is affected, rising to 30% in the over-75 year-old age
group [38].
Dietary sources of lutein and zeaxanthin
Lutein is a common carotenoid found in most fruits and
vegetables, while zeaxanthin is present only in minute
quantities in most fruits and vegetables [39,40]. Dietary
sources of zeaxanthin are limited to greens, certain yel-
low/ orange fruits and vegetables such as corn, nectarines,
oranges, papaya and squash. Orange pepper is recently
found to have a high amount of zeaxanthin [40] and the
dried fruit of Lycium barbarum (fructus lycii) prescribed
by the Chinese herbalist as a therapeutic agent for a
number of eye diseases, has been shown to have a high
content of zeaxanthin but negligible amount of lutein
[41].
The highest mole percentage of both lutein and zeaxan-
thin can be found in egg yolk and maize [40]. Substantial
amounts of lutein are also known to be found in melon,
spinach [41], collards, kale [42], and guava. In 1998, the
United States department of Agriculture (USDA) updatedPage 2 of 8
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centrations of lutein and zeaxanthin in the most common
fruits and vegetable consumed. http://www.nal.usda.gov/
fnic/foodcomp/Data/car98/car98.html.
Pharmaceutical ocular vitamin and mineral supplements – the 
vitamin/mineral supplement controversy
The pharmaceutical industry also provides patients with
various brands of ocular vitamin supplement products all
claiming superiority over their competitors. Some of the
brands of these ocular vitamins include: I Caps, Maxivi-
sion, Ocuguard, Ocuvite, Ocuvite Extra, Ocuvite PreserVi-
sion, Ocuvite Lutein, and Vizion. Supplementation with
foods rich in lutein and zeaxanthin [19] or with lutein rich
supplements [21,22] increases macular pigment density
in most, but not all, human subjects. Nutritional supple-
ments are therefore promoted actively by the vitamin
industry in the United States to individuals at risk for
AMD. Yet the benefits of ocular antioxidant carotenoid
containing vitamin and mineral supplements in patients
with ARM, or those at risk of developing the disease
remain unproved.
The relation of fasting plasma levels of retinol, ascorbate,
alpha-tocopherol, beta-carotene and the use of vitamin
supplements has shown that alpha tocopherol, and an
antioxidant index including alpha tocopherol, beta-caro-
tene, and ascorbate were protective for ARM [43]. How-
ever, no evidence of the protective effect of vitamin
supplements was found in this study. In other studies dis-
cordant responses of serum and retina to dietary supple-
mentation were observed. Serum lutein increased rapidly
after supplementation in individuals, but macular pig-
ment density increased only after several weeks of supple-
mentation [19,22,44]. Some studies have shown no effect
of supplementation with purified or synthetic beta-caro-
tene on the concentrations of several plasma carotenoids
[45-48]. In contrast, other studies have shown that puri-
fied or synthetic beta-carotene can diminish concentra-
tions of lutein [49-51]. Hammond et al have reported that
out of 13 subjects given supplemental dietary sources of
lutein and zeaxanthin 2 subjects were retinal non-
responders- that is, they had significant increases in serum
lutein, but not in macular pigment density [19]. Recently
the evidence of a higher incidence of cancer among ciga-
rette smokers who received beta-carotene supplements in
2 studies [52,53], was reported. Although beta carotene is
considered safe because its conversion to vitamin A is lim-
ited [54], the ATBC study reported a significantly higher
mortality among treated than non-treated subjects. To our
knowledge published data concerning the toxicity of
lutein and zeaxanthin or the optimum dosage or combi-
nation of these antioxidant vitamin/ mineral supplements
is lacking. The Age-Related Eye Disease Study (AREDS),
under the auspices of the National Eye Institute of the
National Institutes of Health, is carefully following two
large cohorts of patients with AMD – one group is being
treated with an Ocuvite formula, the other with a placebo.
When the results of this study begin to be released in five
to ten years, further guidance may become known.
The impact of zinc and other antioxidants on ARM
There seems to be some support in early clinical and epi-
demiological studies for the association of zinc and anti-
oxidant nutrients with ARM. In a small clinical trial, high-
dose zinc supplementation has been reported to reduce
the loss of visual acuity in patients with macular degener-
ation [55]. Yet other studies were only weakly supportive
of the protective effect of zinc on the development of early
ARM [56]. More recently, the Age-Related Eye Disease
Study (AREDS), research group found a beneficial effect
for supplementation with a combination zinc, vitamin E,
vitamin C, and beta-carotene in individuals at high risk
for disease progression to advanced AMD [57]. Results of
this study showed that for patients at high risk of develop-
ing advanced stages of AMD, use of the combination of
antioxidants and zinc supplements reduced that risk by
25%. For the same group, the risk of vision itself was
reduced by 19%. Prospective studies conducted over time,
with greater variability in zinc intake in the Beaver Dam
population are under way and shall provide further esti-
mates on the protective effect of zinc.
Transport and uptake mechanisms of the carotenoids
The biochemical mechanisms that mediate the selective
uptake, concentration, and stabilisation of the of the mac-
ular carotenoids are unknown. In lower animals, such as
lobsters and cyanobacteria, specialised carotenoid-bind-
ing proteins perform these tasks. Much less is known
about carotenoid-binding proteins derived from verte-
brates, yet it has been hypothesised that comparable caro-
tenoid-binding proteins may have a similar role in the
human macula. In the human blood stream, high-density
lipoprotein (HDL) is the major carrier of lutein and zeax-
anthin, while carotenes are preferentially carried by low-
density lipoprotein (LDL) [58]. In the mammalian eye, it
has been reported that retinal tubulin binds macular car-
otenoids [59], possibly as a site for passive deposition in
the tissue. Further postulations included the assumption
that human macular membranes could be a rich source of
specific binding proteins for the macular carotenoids,
especially since many plant and invertebrate carotenoid-
binding proteins are known to be membrane associated
[60,61]. In a recent report, xanthophyll-binding proteins
(XBP) were partially purified and isolated from the
human macula and retina and it was shown that lutein
and zeaxanthin bind specifically to these proteins [62].
Available evidence further suggests the presence of tissue
competition for plasma carotenoids. The concept that adi-
pose tissue and retina may compete for dietary lutein hasPage 3 of 8
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noids during intestinal absorption has also been investi-
gated [63]. It has hypothesised that if adipose tissue and
liver compete with the retina for dietary lutein as sug-
gested by observations in human subjects [44], macular
pigment may be more effectively increased through sup-
plementation with zeaxanthin than with lutein (preferen-
tially absorbed by fat). There is no evidence in literature
suggesting that zeaxanthin can be converted to lutein in
serum or retina, but the reverse has been proposed by
some authors [64,65]. Dietary lutein may serve as a pre-
cursor for the very high concentrations of zeaxanthin
found in the primate fovea, [64] and conversion of lutein
to mesozeaxanthin has been suggested [66].
Controversial evidence on the beneficial effects of 
carotenoids and other antioxidant vitamins in modulating 
the course of AMD
Epidemiological evidence
Some epidemiological evidence suggest a beneficial role
for carotenoids and antioxidant vitamins in the preven-
tion of AMD [31,67,68]. In contrast, in a case control
study consisting of subjects with late AMD, exudative
AMD, and retinal pigment abnormalities with the pres-
ence of drusen, and an equal number of control subjects,
the serum concentrations of lutein and zeaxanthin were
found to be unrelated to the risk of incidence of AMD
[69]. Lower risk for macular degeneration has been asso-
ciated with the consumption of food sources of these car-
otenoids [70], with overall level of lutein and zeaxanthin
in the diet [68,71], or with higher levels of these caroten-
oids in the blood [31]. However, in several studies, these
associations were not observed [56,72] or were observed
only in population subgroups [71]. Other epidemiologi-
cal studies have reported a protective effect against lung
cancer of foods rich in beta-carotene [73]. This finding has
been contradicted in two recent studies in which supranu-
tritional doses of beta-carotene (25–50 mg/day) supple-
mented to smokers during 6 y had a higher incidence of
lung cancer than did the placebo-treated control subjects
[52,74]. Please see table 1, additional file 1.
Experimental evidence
The body of evidence available from studies in laboratory
animals that supports associations between the intake of
antioxidant nutrients and ARM is inconsistent. Several
antioxidant nutrients known to affect retinal degeneration
in animals have not been found to consistently correlate
with macular degeneration in humans. In macaque mon-
keys fed diets devoid of all sources of carotenoid pigment,
levels of these pigments in the macula disappear and reti-
nal abnormalities (drusen formation), an early sign of
ARM appear [75]. In contrast, inverse associations with
several carotenoids in the serum [43,69] or diet and early
ARM have not been documented in studies in humans.
In a recent study done on rhesus monkeys serum levels
and macular density of zeaxanthin was raised by feeding
monkeys a carotenoid-containing fraction of fructus lycii
also known as Gou Qi Zi [76]. This was contrary to the
study by Snodderly et al [77] where no change in the con-
centration of serum lutein was noted after supplementa-
tion of zeaxanthin in squirrel monkeys.
A potential animal model in which to study the protective
effects of these carotenoids is the quail. The quail retina
has been shown to selectively accumulate lutein and zeax-
anthin [78,79] and quail retina has been shown to exhibit
age-related loss of photoreceptors [80]. Preliminary stud-
ies indicate an inverse correlation between the level of
zeaxanthin in quail retina and light-induced cell death
[81,82]. Further studies report that quail fed for 6 months
on zeaxanthin-supplemented diets have an almost 5-fold
elevation in retinal zeaxanthin, and a more than 45-fold
increase in zeaxanthin concentrations in serum, liver and
fat [79].
Reports on other antioxidant vitamins are also controver-
sial. Supplementation of rats with vitamin C has been
reported to reduce retinal damage due to intense light
exposure [83]. However, several other human studies that
have examined levels of vitamin C in the serum [43,67] or
foods [68,70] have found similar statistically significant
associations. Reports have shown that animals with diets
deficient in vitamin E have increased retinal damage [84],
although supplementation with this nutrient does not
protect against light damage [85]. In human studies, one
study [43], but not 3 others [67,69,86], have found low
levels of this nutrient in the serum to be associated with
lower risk for various forms of ARM.
Clinical evidence
Of the hypothesis that macular pigment protects against
AMD was a study in which risk factors for AMD namely,
age and advanced disease in the fellow eye, were shown to
be associated with a relative absence of macular pigment
[87]. Recently an autopsy study has reported that eyes
from donors with a history of AMD had lower levels of
macular carotenoids than eyes without a known history of
AMD [88], although studies relying on post mortem anal-
ysis and retrospective reviews of clinical records after
death have substantial limitations.
In some studies MP density was changed by dietary mod-
ification or through lutein supplementation [21,22]. In
another study, some subjects failed to show a change in
MP density after increasing their dietary intake of lutein
and zeaxanthin [19]. Evidence in favour of changing the
dietary intake of fat soluble vitamins to protect against
AMD has been contradicted by some authors [89].
Reports have also been made on the influence of factorsPage 4 of 8
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sity and serum concentrations of lutein and zeaxanthin
[90,91], yet these associations were evaluated in small
study samples. Please see table 2, additional file 2.
Effect of light and genetic influence on ARM
It has been suggested that the exposure of the retina to
light can promote the development of macular degenera-
tion [92]. Increased risk for late AMD was associated with
increased exposure to blue and visible light in a case con-
trol study of Chesapeake watermen [93,94] and with
increased exposure to sunlight in the Beaver Dam Eye
Study [95]. Light exposure can also increase the produc-
tion of free radicals in the lens and retina [96]. Epidemio-
logical data to support a damaging role of light in macular
degeneration is inconsistent [97], although the difficulty
in capturing actual light exposure over many years in the
participants studied must be taken into account.
Several results on genetic studies with ARM have been
published. First-degree relatives of ARM patients are
between 2 to 4 times greater at risk of developing ARM in
comparison to controls [98]. Twin studies have shown
high levels of concordance of the disease among
monozygous sibs [99,100]. Careful segregation analyses
on a large study of 564 families suggest that a single major
gene accounts for 89–97% of the genetic variability or 55–
57% of the total variability [101]. Even so, relatively little
is known about identified genetic risk factors for ARM and
controversial reports exist supporting genetic variations
[102,103].
Treatment options for ARM and future hopes
Some of the clinical approaches to treating AMD include
novel laser therapies (photodynamic laser therapy, PDT),
surgery (submacular and macular translocation surgery),
chemotherapeutic agents (angiogenesis inhibitors such as
thaliomide, interferon, vascular endothelial growth factor
inhibitors), radiation (external beam/ teletherapy or epis-
cleral plaque/bracytherapy), transplantation of retinal
pigment epithelium and photoreceptors, and gene ther-
apy.
One of the more promising therapies is photodynamic
therapy (PDT). A light activated drug is administered
intravenously, followed by a waiting period of several
minutes to allow the neovascular network of vessels to
bind and absorb the drug. Laser light is then applied to the
now pharmacologically-sensitised target tissues resulting
in precise demise of the microvascular network. This proc-
ess spares the overlying elements, whereas surgery and
radiation could cause retinal scar formation.
Recently, a combination of PDT along with intravitreal
steroid (triamcinolone-acetonide) injections has been
introduced. Steroid compounds are well known antiang-
iogenic agents which have been suggested as treatment for
the choroidal neovascular membranes that cause visual
loss in ARM [104,105]. We hope to release the results of
the study done on a cohort of patients treated with triam-
cinolone and PDT, along with a control group of patients
treated with PDT, within one year. Much of our hope for
successful future treatments also lies in the areas of sup-
pression or modification of neovascular response with
novel anti-antiogenic factors and gene therapy.
Discussion
The information available provides an indication that the
carotenoids, lutein and zeaxanthin, may play a role in
modulating the course of AMD, yet critical evidence of the
beneficial effect has not been found, and crucial informa-
tion for the most effective design of clinical trials is
needed [106]. For the clinician it is clear that this area of
research is only beginning to evolve and further research
is indicated. There is no doubt that any scientific support
for the use of these carotenoids and /or other vitamins or
minerals with antioxidant properties will boost the supply
of these supplements on pharmacy shelves, despite the
unproved benefits. As of yet the long-term physiological
consequences of taking ocular vitamin supplements are
unknown, and until the optimum combination and dos-
age of these ocular antioxidant vitamins and minerals has
been proven and their long-term safety established, the
routine prescription of vitamin/mineral supplements can-
not be justified.
We finally suggest that clinicians inform their patients
that there is no agreement among scientists and doctors to
the benefit of supplementation and we urge them to be
cautious when prescribing ocular vitamin/mineral sup-
plements. However, patients with ARM or at risk of devel-
oping the disease, should be encouraged to eat a balanced
diet rich in fruits and vegetables, and in particular they
should be informed by they clinician on the dietary
sources rich in these carotenoids. We further recommend
patients to wear UV protective lenses and a hat or cap
when outdoors and suggest they see their primary care
physician to treat any hypertension, hypercholesterolemia
or potentially compromising vascular disease. We truly
hope that future investigations on the role of nutrition,




Summary of major epidemiological studies suggesting or contradicting a 
beneficial role of the carotenoids or other antioxidants in altering the 
pathogenesis of macular degeneration.
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